Guideline:

Vitamin A supplementation in pregnancy for reducing the risk of mother-to-child transmission of HIV
# Contents

Acknowledgements  iv  
Financial support  iv  
Summary  1  
Scope and purpose  2  
Background  2  
Summary of evidence  3  
Recommendation  4  
Remarks  4  
Dissemination  4  
Implications for future research  4  
Guideline development process  5  

**Advisory groups**  
Scope of the guideline, evidence appraisal and decision-making  
Management of conflicts of interest  7  
Plans for updating the guideline  8  
References  9  

**Annex 1**  
GRADE “Summary of findings” table  11  

**Annex 2**  
Members of the WHO/UNICEF Steering Committee for guidelines on vitamin A supplementation  12  

**Annex 3**  
Members of the Vitamin A Supplementation Guideline Group, WHO Secretariat and external resource experts  13  

**Annex 4**  
Members of the External Experts and Stakeholders Panel  16  

**Annex 5**  
Questions in Population, Intervention, Control, Outcomes (PICO) format  19  

**Annex 6**  
Summary of considerations for determining the strength of the recommendation  20
Acknowledgements

This guideline was coordinated by Dr Lisa Rogers under the supervision of Dr Juan Pablo Peña-Rosas, with technical input from Dr Rajiv Bahl, Dr Luz Maria de Regil, Ms Tracey Goodman and Dr Jose Martines. Thanks are due to Dr Regina Kulier and the staff at the Guidelines Review Committee Secretariat for their support throughout the process. Thanks are also due to Dr Davina Ghersi for her technical advice and assistance in the preparation of the technical consultations for this guideline and Mr Issa T. Matta and Mrs Chantal Streijffert Garon from the World Health Organization (WHO) Office of the Legal Counsel for their support in the management of conflicts of interest procedures. Ms Grace Rob and Mrs Paule Pillard from the Micronutrients Unit, Department of Nutrition for Health and Development, provided logistic support.

WHO gratefully acknowledges the technical input of the members of the WHO/United Nations Children’s Fund (UNICEF) Steering Committee, the Vitamin A Supplementation Guideline Group and the External Experts and Stakeholders Panel. WHO is also grateful to the Cochrane Editorial Unit for its support in coordinating the update of the systematic reviews used to inform this guideline and the evidence summary of findings.

Financial support

WHO thanks the Government of Luxembourg for providing financial support for this work.
Vitamin A supplementation in pregnancy for reducing the risk of mother-to-child transmission of HIV

Summary

Over 1000 new cases of mother-to-child transmission of the human immunodeficiency virus (HIV) occur worldwide every day, making this the main route of transmission of HIV infection in children. Vitamin A deficiency affects about 19 million pregnant women, mostly from the WHO regions of Africa and South-East Asia. Both HIV infection and pregnancy are considered to be risk factors for vitamin A deficiency. During pregnancy, vitamin A is essential for maternal health and for the healthy development of the fetus. Member States have requested guidance from the World Health Organization (WHO) on the effects and safety of vitamin A supplements for HIV-positive pregnant women as a public health strategy.

WHO has developed the present evidence-informed recommendations using the procedures outlined in the WHO handbook for guideline development. The steps in this process included: (i) identification of priority questions and outcomes; (ii) retrieval of the evidence; (iii) assessment and synthesis of the evidence; (iv) formulation of recommendations, including future research priorities; and (v) planning for dissemination, implementation, impact evaluation and updating of the guideline. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was followed to prepare evidence profiles related to preselected topics, based on up-to-date systematic reviews. An international, multidisciplinary group of experts participated in two WHO technical consultations, held in Geneva, Switzerland, on 19–20 October 2009 and 16–18 March 2011, to review and discuss the evidence and draft recommendation, and to vote on the strength of the recommendation, taking into consideration: (i) desirable and undesirable effects of this intervention; (ii) the quality of the available evidence; (iii) values and preferences related to the intervention in different settings; and (iv) the cost of options available to health-care workers in different settings. All guideline group members completed a Declaration of Interests Form before each meeting. An External Experts and Stakeholders Panel was involved throughout the process.

Vitamin A supplementation in HIV-positive pregnant women is not recommended as a public health intervention for the prevention of mother-to-child transmission of HIV (strong recommendation). The quality of the available evidence was found to be moderate for mother-to-child transmission of HIV and child death, and very low for maternal death. All pregnant women, including those living with HIV/acquired immune deficiency syndrome (AIDS), should be encouraged to receive adequate nutrition through consumption of a healthy balanced diet.

---

1 This publication is a WHO guideline. A WHO guideline is any document, whatever its title, containing WHO recommendations about health interventions, whether they be clinical, public health or policy interventions. A recommendation provides information about what policy-makers, health-care providers or patients should do. It implies a choice between different interventions that have an impact on health and that have ramifications for the use of resources. All publications containing WHO recommendations are approved by the WHO Guidelines Review Committee.
This guideline provides global, evidence-informed recommendations on the use of vitamin A supplements for reducing the risk of mother-to-child transmission of the human immunodeficiency virus (HIV) in populations where vitamin A deficiency may be a public health concern.

The guideline will help Member States and their partners in their efforts to make informed decisions on the appropriate nutrition actions to achieve the Millennium Development Goals, in particular, reduction in child mortality (MDG 4), improvement in maternal health (MDG 5) and combating HIV/acquired immune deficiency syndrome (AIDS), malaria and other diseases (MDG 6). The guideline is intended for a wide audience including policy-makers, their expert advisers, and technical and programme staff in organizations involved in the design, implementation and scaling-up of nutrition actions for public health.

This document presents the key recommendation and a summary of the supporting evidence. Further details of the evidence base are provided in Annex 1 and other documents listed in the references.

Background

In 2009, an estimated 370,000 children contracted HIV in the perinatal or breastfeeding period (1). Over 1000 new cases of mother-to-child transmission of HIV occur daily worldwide, making this the main route of transmission of HIV infection in children (1, 2). The transmission of the virus from the mother to the child can occur during pregnancy, delivery or while breastfeeding (3–5). The severity of maternal HIV infection, the vaginal mode of delivery and presence of advanced HIV disease can increase the risk of transmission. Nutritional status can also be a contributing factor and vitamin A deficiency has been associated with an increase in the risk of transmission of the virus from mother to child (2, 4).

Vitamin A deficiency remains a public health problem among women, affecting an estimated 19 million pregnant women (6), with the highest burden found in the World Health Organization (WHO) regions of Africa and South-East Asia. During pregnancy, vitamin A is essential for the health of the mother as well as for the health and development of the fetus. This is because vitamin A is important for cell division, fetal organ and skeletal growth, maintenance of the immune system to strengthen defences against infection, and development of vision in the fetus as well as maintenance of maternal eye health and night vision (7, 8). During pregnancy, serum retinol levels decline, particularly in the third trimester; this may be due to the physiological increment in blood volume or due to an acute phase response, and it can be exacerbated by an inadequate vitamin A intake (9, 10). Night blindness, an early sign of vitamin A deficiency, is associated with infectious diseases (4, 10). Both HIV infection and pregnancy are considered to be risk factors for vitamin A deficiency (11).

Current strategies to reduce mother-to-child transmission of HIV include antiretroviral therapy (ART), elective caesarean section delivery and use of the most appropriate infant feeding options (12–15). However, in some low- and middle-
income countries with high rates of infections, these strategies might not practical because of the costs associated with the need to determine the HIV status of the mother and the need for skilled personnel for delivery (2, 5, 12, 16); hence effective, affordable and simple strategies are needed for the prevention of mother-to-child transmission of HIV. Because a pregnant HIV-infected woman and her child are susceptible to nutritional deficiencies, including vitamin A (4), and because vitamin A plays an important role in immune function (17–19), vitamin A supplementation in pregnancy has been suggested as a potential low-cost intervention to reduce the risk of mother-to-child transmission of HIV. The acute phase response to infection can reduce serum retinol concentrations (20) used to determine vitamin A status. Observational studies have shown a link between low serum retinol and disease severity or the risk of mother-to-child transmission of HIV. Thus, the levels of serum retinol may not be a reliable predictor of the efficacy of a vitamin A intervention because low serum retinol in such situations may be more an index of disease severity rather than nutritional status.

In countries where vitamin A deficiency is a public health problem, WHO recommends periodic administration of high-dose vitamin A supplements to children 6–59 months of age to reduce mortality (21). Although vitamin A supplements are not recommended as part of routine antenatal care for the prevention of maternal and infant morbidity and mortality, they are recommended in pregnant women for the prevention of night blindness in areas where there is a severe public health problem of vitamin A deficiency (22). The evidence for benefits of vitamin A supplementation in HIV-positive women for the prevention of mother-to-child transmission of HIV in observational studies has been conflicting thus far (2).

An updated Cochrane systematic review was used to assess the effects and safety of vitamin A supplements in reducing the risk of mother-to-child transmission of HIV (2). This review also evaluated the effect of vitamin A supplementation in HIV-positive women on infant and maternal mortality and morbidity. A meta-analysis indicated that vitamin A supplementation in HIV-positive pregnant women has no significant effect on mother-to-child transmission of HIV compared with controls in children followed up at 3–24 months of age (three trials: risk ratio (RR) 1.05; 95% confidence interval (CI) 0.78–1.41). However, there was significant heterogeneity in the results of the trials, with one trial showing a significant increase in mother-to-child transmission of HIV (23). There was no evidence that vitamin A supplementation in HIV-positive pregnant women had an effect on maternal death (one trial: RR 0.49; 95% CI 0.04–5.37) or child death by 24 months of age (two trials: RR 1.03; 95% CI 0.88–1.20). None of the trials provided any information on the potential adverse effects of vitamin A supplementation in pregnancy.

The overall quality of the available evidence for the outcomes of mother-to-child transmission of HIV and child death was graded as moderate, whereas the quality of evidence for the outcome of maternal death was very low (Annex 1).
Vitamin A supplementation in HIV-positive pregnant women is not recommended as a public health intervention for reducing the risk of mother-to-child transmission of HIV (strong recommendation\(^1\)).

**Remarks**

- Women should be encouraged to receive adequate nutrition, which is best achieved through consumption of a healthy balanced diet, and to refer to guidelines on nutrient requirements for people living with HIV/AIDS (24) and guidelines on HIV and infant feeding (15).
- Recommendations for the treatment of xerophthalmia are not covered in this guideline. Existing guidelines for the treatment of xerophthalmia in women of reproductive age should be referred to in these cases (25).

**Dissemination**

The current guideline will be disseminated through electronic media such as slide presentations, CD-ROMs and the World Wide Web, either through the WHO Micronutrients and United Nations Standing Committee on Nutrition (SCN) mailing lists or the [WHO nutrition web site](https://www.who.int/nutrition). Currently, the WHO Department of Nutrition for Health and Development is developing the WHO electronic Library of Evidence for Nutrition Actions (eLENA). This library aims to compile and display WHO guidelines related to nutrition along with complementary documents such as systematic reviews and other evidence informing the guidelines, biological and behavioural rationales, and additional resources produced by Member States and global partners.

**Implications for future research**

- The guideline group members agreed that additional research in this area is of low priority.
- If new research is to be conducted, an appropriately powered, randomized controlled trial to assess the additive effect of vitamin A supplementation in pregnant women being treated with ART on the risk of mother-to-child transmission of HIV may be helpful.

---

\(^1\) A strong recommendation is one for which the guideline development group is confident that the desirable effects of adherence outweigh the undesirable effects. The recommendation can be either in favour of or against an intervention. Implications of a strong recommendation for patients are that most people in their situation would desire the recommended course of action and only a small proportion would not. For clinicians, the implications are that most patients should receive the recommended course of action and that adherence to this recommendation is a reasonable measure of good-quality care. With regard to policy-makers, a strong recommendation means that it can be adapted as a policy in most situations.
This guideline was developed in accordance with the WHO evidence-informed guideline development procedures, as outlined in the *WHO handbook for guideline development* (26).

**Advisory groups**

A WHO/United Nations Children's Fund (UNICEF) Steering Committee for Guidelines on Vitamin A Supplementation was established in 2009 with representatives from the WHO departments of Child and Adolescent Health and Development; Immunizations, Vaccines and Biologicals; Making Pregnancy Safer; Nutrition for Health and Development; Reproductive Health and Research; and the Nutrition Section of UNICEF (Annex 2). The Steering Committee guided the development of this guideline and provided overall supervision of the guideline development process. Two additional groups were formed: an advisory guideline group and an External Experts and Stakeholders Panel.

The guideline group included experts from various WHO expert advisory panels and those identified through open calls for specialists, taking into consideration a balanced gender mix, multiple disciplinary areas of expertise and representation from all WHO regions (Annex 3). Efforts were made to include content experts, methodologists, representatives of potential stakeholders (such as managers and other health professionals involved in the health-care process) and consumers. Representatives of commercial organizations may not be members of a WHO guideline group. The role of the guideline group was to advise WHO on the choice of important outcomes for decision-making and the interpretation of the evidence.

The External Experts and Stakeholders Panel was consulted on the scope of the document, the questions addressed and the choice of important outcomes for decision-making, as well as with regard to review of the completed draft guideline (Annex 4). This was done through the WHO Micronutrients and SCN mailing lists, which together include over 5500 subscribers, and through the WHO nutrition website.

**Scope of the guideline, evidence appraisal and decision-making**

An initial set of questions (and the components of the questions) to be addressed in the guideline was the critical starting point for formulating the recommendation; the questions were drafted by technical staff at the Micronutrients Unit, Department of Nutrition for Health and Development, in collaboration with the Nutrition Section of UNICEF, based on policy and programme guidance needs of Member States and their partners. The population, intervention, control, outcomes (PICO) format was used (Annex 5). The questions were discussed and reviewed by the Steering Committee and feedback was received from 45 stakeholders.

The first guideline group meeting was held on 19–20 October 2009 in Geneva, Switzerland, to finalize the scope of the questions and rank the critical outcomes and populations of interest. The guideline group members discussed the relevance of each question and modified them as needed. They scored the relative importance of each outcome from 1 to 9 (where 7–9 indicated that the outcome was critical for a
decision, 4–6 indicated that it was important and 1–3 indicated that it was not important). The final key question on vitamin A supplementation in pregnancy for reducing the risk of mother-to-child transmission of HIV, along with the outcomes that were identified as critical for decision-making, are listed in PICO format in Annex 5.

The Cochrane Collaboration was commissioned to search, review and generate systematic reviews, evidence profiles and the “Summary of findings” table\(^1\) (Annex 1). One existing Cochrane review on vitamin A supplementation in pregnancy for reducing the risk of mother-to-child transmission of HIV was updated, and the up-to-date Review Manager Software (RevMan) file, obtained from the Cochrane Editorial Unit, was customized in order to reflect the critical outcomes previously identified (outcomes not relevant to this guideline were excluded). The RevMan file was exported to the GRADE profiler software in order to prepare the evidence summaries according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach for assessing the overall quality of the available evidence (27) (Annex 1). GRADE considers: the study design; the limitations of the studies in terms of their conduct and analysis; the consistency of the results across the available studies; the directness (or applicability and external validity) of the evidence with respect to the populations, interventions and settings where the proposed intervention may be used; and the precision of the summary estimate of the effect.

Both the systematic review and the GRADE evidence profiles for each of the critical outcomes were used for drafting the guideline. A second guideline group meeting was held on 16–18 March 2011 in Geneva, Switzerland, to review the evidence and discuss the draft recommendation and determine its strength, taking into consideration: (i) desirable and undesirable effects of this intervention; (ii) quality of the available evidence; (iii) values and preferences related to the intervention in different settings; and (iv) the cost of options available to health-care workers in different settings (Annex 6). Consensus was defined as agreement by simple majority of the guideline group members. WHO staff present at the meeting as well as other external technical experts involved in the collection and grading of the evidence were not allowed to vote. There were no strong disagreements among the guideline group members.

The External Experts and Stakeholders Panel was again consulted on the draft guideline. Feedback was received from 12 stakeholders. WHO staff then finalized the guideline and submitted it for clearance by WHO before publication.

---

\(^1\) As part of the Cochrane pre-publication editorial process, reviews are commented on by external peers (an editor and two referees external to the editorial team) and the group’s statistical adviser (http://www.cochrane.org/cochrane-reviews). The Cochrane handbook for systematic reviews of interventions describes in detail the process of preparing and maintaining Cochrane systematic reviews on the effects of health-care interventions.
Management of conflicts of interest

According to the rules in the WHO Basic documents (28), all experts participating in WHO meetings must declare any interest relevant to the meeting prior to their participation. The conflicts of interest statements for all guideline group members were reviewed by the responsible technical officer and the relevant departments before finalization of the group composition and invitation to attend a guideline group meeting. All guideline group members and participants of the guideline development meetings submitted a Declaration of Interests Form along with their curriculum vitae before each meeting. In addition, they verbally declared potential conflicts of interest at the beginning of each meeting. The procedures for management of conflicts of interests strictly followed the WHO Guidelines for declaration of interests (WHO experts) (29). The potential conflicts of interest declared by members of the guideline group are summarized below.

- Professor Michael Clarke declared being Director of the UK Cochrane Centre and a member of The Cochrane Collaboration. Professor Clarke was not personally involved in the preparation or management of the systematic reviews on vitamin A supplementation used for this guideline, although some of his colleagues were involved.

- Dr Jean Humphrey declared that her research unit received research grants from 1996 to 2009 for the Zimbabwe Vitamin A for Mothers and Babies Project (ZVITAMBO) from various organizations, including the Nestlé Foundation, BASF and the Pediatric AIDS Foundation, which receives its core funds from various organizations including Johnson & Johnson and the Abbott Fund. Sub-studies were also supported by Support for Analysis and Research in Africa (SARA) and Linkages Projects, both managed by the Academy for Educational Development (AED). To our knowledge, other than BASF, none of these companies nor their commercial sponsors directly or indirectly produce vitamin A supplements.

- Dr Charles Stephensen declared receiving research funds from WHO for the conduct of a human study on the efficacy of newborn vitamin A supplementation in improving immune function and from the United States National Institutes of Health for the conduct of studies on vitamin A and immune function in mice.

- Dr Sherry Tanumihardjo declared receiving remuneration as a technical consultant for the International Atomic Energy Agency (IAEA) and an honorarium from HarvestPlus. She also received research support from: HarvestPlus for a vitamin A efficacy study in Zambian children fed orange maize and for a banana study in gerbils to determine the vitamin A value of provitamin A carotenoids; the United States National Institutes of Health for developing a 13C retinol isotope dilution test; the United States Department of Agriculture (USDA) for the use of α-retinol as a chylomicron tag in rats and pigs; and WHO for mechanistic studies to understand neonatal vitamin A supplementation using the sow-piglet dyad model. In addition, she received reimbursement for travel expenses from IAEA, HarvestPlus and WHO to
Vitamin A supplementation in pregnancy for reducing the risk of mother-to-child transmission of HIV

Plans for updating the guideline

A vitamin A trial conducted between September 1997 and December 2000 in Bloemfontein, Free State, South Africa, has been identified (30, 31) but it has not yet been published.

The recommendation in this guideline will be reviewed in 2014. If new information is available at that time, a guideline review group will be convened to evaluate the new evidence and revise the recommendation. The Department of Nutrition for Health and Development at the WHO headquarters in Geneva, along with its internal partners, will be responsible for coordinating the guideline update following the formal WHO handbook for guideline development (26) procedures. WHO welcomes suggestions regarding additional questions for evaluation in this guideline when it is due for review.
References


### Annex 1  GRADE “Summary of findings” table

**Vitamin A supplementation in pregnancy for reducing the risk of mother-to-child transmission of HIV**

**Patient or population:** HIV-positive pregnant women  
**Settings:** Low- and middle-income countries  
**Intervention:** Vitamin A supplementation

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Relative effect (95% CI)</th>
<th>Number of participants (studies)</th>
<th>Quality of the evidence (GRADE)*</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal mortality</td>
<td>RR 0.49 (0.04–5.37)</td>
<td>728 (1 study)</td>
<td>⊕⊕⊕⊕ very low</td>
<td>Only one study reported on this outcome</td>
</tr>
<tr>
<td>Viral load/CD4 count (adverse effects) during pregnancy</td>
<td>Not estimable</td>
<td>0 (0 studies)</td>
<td></td>
<td>None of the studies reported on this outcome</td>
</tr>
<tr>
<td>HIV infection in child</td>
<td>RR 1.05 (0.78–1.41)</td>
<td>2022 (3 studies)</td>
<td>⊕⊕⊕ moderate</td>
<td></td>
</tr>
<tr>
<td>Follow-up: 3–24 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Child mortality</td>
<td>RR 1.03 (0.88–1.20)</td>
<td>1635 (2 studies)</td>
<td>⊕⊕⊕ moderate</td>
<td>None of the studies reported on this outcome</td>
</tr>
<tr>
<td>Follow-up: 24 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CI, confidence interval; RR, risk ratio; HIV, human immunodeficiency virus.  
* GRADE Working Group grades of evidence:  
**High quality:** We are very confident that the true effect lies close to that of the estimate of the effect.  
**Moderate quality:** We have moderate confidence in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.  
**Low quality:** Our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.  
**Very low quality:** We have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of the effect.  

1 Allocation, generation and concealment were not described. The study had an unclear risk of bias.  
2 In view of the single study that contributed data to this outcome, the degree of inconsistency is unknown rather than unobserved.  
3 The imprecision around the relative effect is compatible with a very large increase in risk and a significant reduction in risk of maternal death.  
4 High level of statistical heterogeneity; study results are discordant.  
5 Wide confidence intervals around the pooled effect estimate.

For details of studies included in the review, see reference (2).
Annex 2

Members of the WHO/UNICEF Steering Committee for guidelines on vitamin A supplementation

**WHO**

Dr Rajiv Bahl  
Medical Officer  
Newborn and Child Health and Development Unit  
Department of Child and Adolescent Health and Development

Ms Tracey Goodman  
Technical Officer  
Expanded Programme on Immunization Plus Unit  
Department of Immunization, Vaccines and Biologicals

Dr Matthews Mathai  
Medical Officer  
Norms and Country Support Cooperation Unit  
Department of Making Pregnancy Safer

Dr Mario Merialdi  
Coordinator  
Improving Maternal and Perinatal Health Unit  
Department of Reproductive Health and Research

Dr Juan Pablo Peña-Rosas  
Coordinator  
Micronutrients Unit  
Department of Nutrition for Health and Development

Dr Lisa Rogers  
Technical Officer  
Micronutrients Unit  
Department of Nutrition for Health and Development

**UNICEF**

Mr Arnold Timmer  
Senior Adviser  
Micronutrients Unit  
UNICEF Nutrition Section
Annex 3

Members of the Vitamin A Supplementation Guideline Group, WHO Secretariat and external resource experts

A. Members of the Vitamin A Supplementation Guideline Group
(Note: the areas of expertise of each guideline group member are given in italics)

**Professor Hany Abdel-Aleem**  
Assiut University Hospital  
Assiut, Egypt  
*Obstetrics and gynaecology*

**Professor Michael Clarke**  
University of Oxford  
Oxford, England  
*Methods*

**Dr Anna Coutsoudis**  
University of KwaZulu-Natal  
Durban, South Africa  
*Vitamin A, infectious disease*

**Dr M. Monir Hossain**  
Bangladesh Institute of Child Health and Dhaka Shishu (Children) Hospital  
Sher-e-Bangla Nagar  
Dhaka, Bangladesh  
*Neonatology*

**Dr Jean Humphrey**  
Zimbabwe Vitamin A for Mothers and Babies Project (ZVITAMBO)  
Harare, Zimbabwe  
*Vitamin A, human immunodeficiency virus (HIV)*

**Dr Yustina Anie Indriastuti**  
Indonesian Medical Doctor Nutrition Society  
Jakarta, Indonesia  
*Programme Manager*

**Dr Marzia Lazzerini**  
Institute for Maternal and Child Health  
Trieste, Italy  
*Methods, paediatrics*

**Dr Pavitra Mohan**  
UNICEF India Country Office  
New Delhi, India  
*Paediatrics*

**Dr Rintaro Mori**  
University of Tokyo  
Tokyo, Japan  
*Paediatrics*

**Dr A. Catherine Ross**  
Pennsylvania State University  
University Park, United States of America  
*Vitamin A, immunology*

**Dr Isabella Sagoe-Moses**  
Ghana Health Service – Ministry of Health  
Accra, Ghana  
*Programme Manager*

**Dr Claudia Saunders**  
Instituto de Nutrição Josué de Castro  
Universidade Federal do Rio de Janeiro  
Rio de Janeiro, Brazil  
*Vitamin A research programmes*

**Dr Prak Sophonneary**  
National Maternal and Child Health Center Ministry of Health  
Phnom Penh, Cambodia  
*Programme Manager*

**Dr Charles Stephensen**  
USDA Western Human Nutrition Research Center  
Davis, United States of America  
*Vitamin A, immunology*

**Dr Sherry Tanumihardjo**  
University of Wisconsin  
Madison, United States of America  
*Vitamin A metabolism*

**Dr Khalid Yunis**  
American University of Beirut  
Beirut, Lebanon  
*Neonatology, perinatology*
B. WHO

Mr Joseph Ashong
Intern (rapporteur)
Micronutrients Unit
Department of Nutrition for Health and Development

Dr Francesco Branca
Director
Department of Nutrition for Health and Development

Ms Emily Cercone
Intern (rapporteur)
Micronutrients Unit
Department of Nutrition for Health and Development

Dr Luz Maria de Regil
Epidemiologist
Micronutrients Unit
Department of Nutrition for Health and Development

Dr Chris Duncombe
Medical Officer
Anti-retroviral Treatment and HIV Care Unit
Department of HIV/AIDS

Dr Davina Ghersi
Team Leader
International Clinical Trials Registry Platform
Department of Research Policy and Cooperation

Dr Ahmet Metin Gulmezoglu
Medical Officer
Technical Cooperation with Countries for Sexual and Reproductive Health
Department of Reproductive Health and Research

Dr Regina Kulier
Scientist
Guideline Review Committee Secretariat
Department of Research Policy and Cooperation

Dr José Martines
Coordinator
Newborn and Child Health and Development Unit
Department of Child and Adolescent Health and Development

Ms Sueko Matsumura
Intern (rapporteur)
Micronutrients Unit
Department of Nutrition for Health and Development

Dr Sant-Rayn Pasricha
Intern (rapporteur)
Micronutrients Unit
Department of Nutrition for Health and Development

C. WHO regional offices

Dr Abel Dushimimana
Medical Officer
WHO Regional Office for Africa
Brazzaville, Congo

Dr Chessa Lutter
Regional Adviser
Unit on Child and Adolescent Health
WHO Regional Office for the Americas/
Pan American Health Organization
Washington, United States of America
Vitamin A supplementation in pregnancy for reducing the risk of mother-to-child transmission of HIV
Annex 4

Members of the External Experts and Stakeholders Panel

A. Members commenting on priority questions on vitamin A supplementation (October 2009)

Engineer Alaa I. Abu Rub  
Ministry of Health  
Palestinian National Authority  
Ramallah, West Bank and Gaza Strip

Dr Clayton Ajello  
Vitamin Angels  
Santa Barbara, United States of America

Dr Mohamed Ag Ayoya  
UNICEF, India Country Office  
New Delhi, India

Professor Hassan Aguenauou  
Ibn Tofail University  
Kénitra, Morocco

Mrs Deena Alasfoor  
Ministry of Health  
Muscat, Oman

Ms Maria Theresa Alvarez  
Academy for Educational Development (AED) – A2Z Project  
Manila, Philippines

Mr Ravi Raj Atrey  
SOS Children’s Villages of India  
New Delhi, India

Mr Shawn Baker  
Helen Keller International  
Dakar-Yoff, Senegal

Dr Christine Stabell Benn  
Bandim Health Project  
Statens Serum Institut  
Copenhagen, Denmark

Dr Djibril Cissé  
Helen Keller International  
Dakar-Yoff, Senegal

Professor Pradeep Deshmukh  
Dr Sushila Nayar School of Public Health  
Mahatma Gandhi Institute of Medical Sciences  
Sewagram, India

Dr Amol Dongre  
Mahatma Gandhi Institute of Medical Sciences  
Sewagram, India

Dr Masako Fujita  
Michigan State University  
East Lansing, United States of America

Dr Bishan Garg  
Dr Sushila Nayar School of Public Health  
Mahatma Gandhi Institute of Medical Sciences  
Sewagram, India

Dr Ajay Gaur  
GR Medical College  
Gwalior, India

Ms Alison Greig  
Micronutrient Initiative  
Ottawa, Canada

Dr Laurence M. Grummer-Strawn  
Centers for Disease Control and Prevention (CDC)  
Atlanta, United States of America

Dr Maria Claret C.M. Hadler  
Federal University of Goiás  
Goiânia, Brazil

Dr Samia Halileh  
Institute of Community and Public Health  
Birzeit University  
Birzeit, West Bank and Gaza Strip
Vitamin A supplementation in pregnancy for reducing the risk of mother-to-child transmission of HIV

Ms Nancy J. Haselow
Helen Keller International
Phnom Penh, Cambodia

Dr Jocelyn A. Juguan
Food and Nutrition Research Institute
Department of Science and Technology
Manila, Philippines

Dr Umesh Kapil
All India Institute of Medical Sciences
New Delhi, India

Dr Chen Ke
Maternal and Children’s Health Care Hospital
Chengdu, China

Dr Klaus Kraemer
Sight and Life
Basel, Switzerland

Mr Hou Kroen
Helen Keller International
Phnom Penh, Cambodia

Dr Anand Lakshman
Micronutrient Initiative
New Delhi, India

Ms Ada Lauren
Vitamin Angels
Santa Barbara, United States of America

Dr Tingyu Li
Children’s Hospital of Chongqing Medical University
Chongqing, China

Dr Georg Lietz
Newcastle University
Newcastle upon Tyne, England

Dr Kurt Long
University of Queensland
Brisbane, Australia

Dr Zeba Mahmud
Micronutrient Initiative
Dhaka, Bangladesh

Dr Najat Mokhtar
Ibn Tofail University
Kénitra, Morocco

Dr Siti Muslimatun
Southeast Asian Ministers of Education Organization
Tropical Medicine and Public Health Network (SEAMEO TROPMED)
Jakarta, Indonesia

Mr Banda Ndiaye
Micronutrient Initiative
Dakar, Senegal

Dr Lakshmi Rahmathullah
Family Health and Development Research Service Foundation
Madurai, India

Professor H.P.S. Sachdev
Maulana Azad Medical College
New Delhi, India

Dr Tina Sanghvi
Academy for Educational Development
Washington, United States of America

Ms Dimple Save
JICA-MP Reproductive Health Project
Bhopal, India

Dr Al Sommer
Johns Hopkins Bloomberg School of Public Health
Baltimore, United States of America

Dr Lize van Stuijvenberg
Medical Research Council
Cape Town, South Africa

Dr Hans Verhoef
London School of Hygiene and Tropical Medicine
London, England

Dr Sheila Vir
Public Health Nutrition and Development Centre
New Delhi, India
Vitamin A supplementation in pregnancy for reducing the risk of mother-to-child transmission of HIV

Dr Tobias Vogt
St Thomas Home and German Doctors Committee
Frankfurt, Germany

Dr David L. Yeung
H.J. Heinz Company Foundation
Toronto, Canada

Dr Jian Zhang Yang
Columbia University
New York, United States of America

Dr Xiao Ying Zheng
Institute of Population Research, Peking University
Beijing, China

B. Members commenting on the draft guideline on vitamin A supplementation (March 2011)

Dr Christine Stabell Benn
Bandim Health Project
Statens Serum Institut
Copenhagen, Denmark

Professor Hans K. Biesalski
Department of Biological Chemistry and Nutrition
Hohenheim University
Stuttgart, Germany

Ms Nita Dalmiya
UNICEF Nutrition Section
New York, United States of America

Ms Alison Greig
Micronutrient Initiative
Ottawa, Canada

Dr Roland Kupka
UNICEF Regional Office for West and Central Africa
Dakar-Yoff, Senegal

Ms Ada Lauren
Vitamin Angels Alliance
Santa Barbara, United States of America

Dr Teresa Murguía Peniche
National Center for Child and Adolescent Health
Mexico City, Mexico

Ms Anna Roesler
Menzies School of Health Research
Casuarina, Australia

Dr Amal Saeed
University of Khartoum
Khartoum, Sudan

Dr Martha Elizabeth van Stuijvenberg
South African Medical Research Council
Cape Town, South Africa

Dr Sheila Vir Chander
Public Health Nutrition and Development Centre
New Delhi, India

Dr Frank Wieringa
Institut de Recherche pour le Développement
Marseilles, France
Annex 5

**Effects and safety of vitamin A supplementation in HIV-positive women during pregnancy**

a. Should vitamin A supplements be given to HIV-positive women during pregnancy to reduce mother-to-child transmission of HIV?

b. If so, at what dose, and frequency and duration for the intervention?

---

**Questions in Population, Intervention, Control, Outcomes (PICO) format**

**Population:**
- HIV-positive pregnant women living in countries where vitamin A deficiency may be of public health concern
- Subpopulations:
  - By antiretroviral therapy (ART): receiving versus not receiving

**Intervention:**
- Any oral vitamin A supplement alone
- Oral vitamin A supplement given in combination with other micronutrients
- Subgroup analysis:
  - Dose and regimen: daily (10,000 IU) or weekly (25,000 IU) versus other doses

**Control:**
- Placebo or no treatment
- Micronutrient supplements without vitamin A (to assess the additive effect of vitamin A)

**Outcomes:**
- **Critical**
  - Maternal
    - Mortality
    - Adverse effects during pregnancy
      - Viral load/CD4 count
  - Infant
    - HIV status of infant
    - All-cause mortality within 0–6, 0–12 and 0–24 months of life

**Setting:**
- All countries
Annex 6  Summary of considerations for determining the strength of the recommendation

Quality of evidence: • Moderate for two critical outcomes from three good randomized controlled trials
• Very low quality of evidence for maternal mortality from only one study with wide confidence intervals

Values and preferences: • No overall benefit on reducing transmission of HIV
• Antiretroviral therapy (ART) is now available (was not available at the time that the trials were conducted)

Trade-off between benefits and harm: • No apparent benefit of vitamin A supplementation
• There is potential for harm (one study) but this is unclear at the present time

Costs and feasibility: • Minimal cost
• Feasible but feasibility may diminish in the light of other more beneficial interventions now available for pregnant women (e.g. ART, iron-folic acid supplementation)
Vitamin A supplementation in pregnancy for reducing the risk of mother-to-child transmission of HIV

For more information, please contact:

Department of Nutrition for Health and Development
World Health Organization
Avenue Appia 20, CH-1211 Geneva 27, Switzerland
Fax: +41 22 791 4156
E-mail: nutrition@who.int
www.who.int/nutrition